Back to the main directory
EarningsReview / Equity
- Q1 25 - first take: Encouraging 2025 EBITDA guidance by BNP Paribas Exane
- Q1 25 first take: orders ahead, 1% adj. EBIT beat, soft FCF temporary by BNP Paribas Exane
- YIT - Gradually turning by Danske Bank Equity Research
- Q125 results: No surprises, guidance reiterated by BNP Paribas Exane
- Q1-25 First Take by BNP Paribas Exane
- Röko - We tip our (student) hats to the performance by Danske Bank Equity Research
- Tietoevry - Things should only get better by Danske Bank Equity Research
- Read across from LOGI Q4 25 by BNP Paribas Exane
- Q1 broadly in line with our expectations and guidance reaffirmed by BNP Paribas Exane
- 科伦博泰生物-B（6990 HK） by HSBC
- Q1 25 - first take: Strong order intake in P&P and Hydro by BNP Paribas Exane
- Results Flash - EBITDA in-line, FCF misses, demand outlook challenging by BNP Paribas Exane
- 1Q25 2% miss but FY25 guidance maintained reflecting back-end loaded biosimilars performance by BNP Paribas Exane
- Q1'25 results: in-line and reassuring FY25 guidance by BNP Paribas Exane
- Q125 sales: Strong beat by BNP Paribas Exane
- Q125 sales: modest beat by BNP Paribas Exane
- Q1 trading update - in line performance, guidance reiterated by BNP Paribas Exane
- 1Q25 results: Results largely in line, FY25 guidance unchanged, positive order outlook confirmed by BNP Paribas Exane
- Instalco - Gearing woes take centre stage by Danske Bank Equity Research
- 1Q first read: P&L slightly light, capital stronger, no mention of Poland by BNP Paribas Exane
- Q1’25 First Take: new segment and regional detail following Apr warning by BNP Paribas Exane
- ENCE: RDOS. 1T’25 (ANÁLISIS BANCO SABADELL) by Sabadell
- Q1-25 First Take by BNP Paribas Exane
- Valeo SE - Une publication en ligne by MidCap Partners
- Solutions 30 - Début d’année en recul by MidCap Partners